China Human Rabies Vaccine For Dog Bite Exposure Prevention Manufacturer, Supplier, Factory

AIM Honor (Ningbo) Biopharmaceutical Co., Ltd. is a professional China manufacturer supplying Human Rabies Vaccine For Dog Bite Exposure Prevention, developed for post-exposure rabies prevention after dog-related injuries. Based on Vero cell culture technology and strict pharmaceutical production management, this vaccine provides reliable immunization support with a complete injection schedule, stable quality, and professional supply capability for global healthcare partners.

Product Overview

AIM Honor provides professional rabies prevention solutions through advanced vaccine manufacturing technology and controlled production processes. This human rabies vaccine product is designed for post-exposure situations caused by dog bites, scratches, and other potential rabies risks, helping medical institutions provide timely vaccination services for exposed individuals.

Human rabies prevention after animal exposure requires professional vaccination management and appropriate medical evaluation. The vaccine developed by AIM Honor uses inactivated rabies virus technology and Vero cell culture technology to support immune response after administration. It is supplied in freeze-dried form and designed for intramuscular injection according to the recommended vaccination schedule.

The conventional version is produced using rabies fixed virus aG strain cultivated on Vero cells. The serum-free version adopts serum-free Vero cell culture technology throughout the production process, avoiding the addition of bovine serum during cell revival, expansion, and virus cultivation stages.

This production approach helps improve process control and reduce risks related to bovine serum residues, supporting consistent vaccine manufacturing quality. Both versions are developed for professional medical applications and meet different supply requirements.

Core Features

The Human Rabies Vaccine For Dog Bite Exposure Prevention combines established vaccine technology with practical application advantages. Its main features include:

1. Vero cell production technology: The vaccine is manufactured through Vero cell culture technology, a commonly applied platform in human vaccine production. Controlled production procedures help maintain product consistency.

2. Complete immunization schedule: The product supports a five-dose post-exposure vaccination schedule, with doses administered on days 0, 3, 7, 14, and 28 according to the supplied product information.

3. Freeze-dried formulation: The vaccine is supplied in freeze-dried form, with 1.0ml per vial after reconstitution, suitable for professional medical administration.

4. Professional manufacturing support: AIM Honor provides pharmaceutical production and supply services for medical institutions, distributors, and healthcare organizations.

Production Technology

The manufacturing process focuses on quality consistency, process control, and product stability. The conventional vaccine version uses inactivated rabies fixed virus aG strain, while the serum-free version uses inactivated rabies fixed virus PV-2061 strain.

The serum-free production process eliminates bovine serum addition during the complete culture process, including cell revival, expansion, and virus cultivation. This technology helps strengthen manufacturing control and supports higher production consistency.

AIM Honor continues to improve vaccine production capabilities through professional research and manufacturing management. The company provides reliable biological product solutions for customers requiring long-term cooperation and stable supply.

Immune Response

After administration according to the recommended schedule, the vaccine stimulates the body to produce rabies-neutralizing antibodies. According to the provided product information, the vaccine achieves a 100% antibody seroconversion rate within 14 days and exceeds the WHO effective protection standard of 0.5 IU/ml.

The conventional version has a potency standard of ≥2.5 IU/dose, with an actual detection mean of approximately 6.0 IU/dose. The serum-free version also meets the potency requirement, with post-immunization antibody GMC significantly higher than the protection threshold.

Product Specification

Quality Assurance

AIM Honor follows professional pharmaceutical manufacturing requirements and focuses on quality management throughout the vaccine production process. From raw material selection and cell culture to filling, freeze-drying, packaging, and final inspection, each production stage requires controlled management to maintain product consistency.

The company combines technical experience with standardized manufacturing procedures to support stable vaccine supply. For healthcare organizations and distributors, reliable production capability and consistent product information are important factors when selecting a long-term vaccine supplier.

The main quality control measures include:

1. Controlled production procedures: Professional manufacturing processes are applied throughout vaccine preparation to support stable product performance.

2. Process monitoring: Key production steps including Vero cell culture, virus preparation, and formulation are managed under controlled conditions.

3. Product inspection: Finished products are evaluated according to relevant quality requirements before delivery to customers.

Application Areas

Rabies prevention requires timely and professional medical support after possible animal exposure. This vaccine product is suitable for multiple healthcare-related application environments where post-exposure vaccination services are required.

1. Hospitals and clinics: Medical institutions can use the Human Rabies Vaccine For Dog Bite Exposure Prevention as part of post-exposure vaccination services for individuals with dog bites, scratches, or other possible rabies exposure risks.

2. Emergency vaccination centers: Emergency departments and vaccination facilities can provide rapid response services after exposure incidents by following professional vaccination procedures.

3. Public health organizations: Disease prevention programs and healthcare projects may require stable vaccine supply to support rabies prevention activities.

4. Pharmaceutical distributors: Healthcare suppliers and distributors can cooperate with AIM Honor for professional vaccine procurement and supply arrangements.

Supply Capability

AIM Honor (Ningbo) Biopharmaceutical Co., Ltd. provides vaccine products supported by professional manufacturing experience and pharmaceutical production capabilities. The company focuses on delivering reliable biological products for healthcare partners in different markets.

For international buyers, stable supply, clear product specifications, and professional communication are essential elements of successful cooperation. AIM Honor supports customers by providing product documentation, technical information, and supply coordination according to procurement requirements.

Through continuous improvement of production technology and manufacturing management, AIM Honor aims to provide dependable solutions for global rabies prevention needs.

Storage And Transportation

Proper storage conditions are essential for maintaining vaccine quality during distribution. According to the supplied product specifications, the vaccine should be stored at 2-8℃ away from light, and freezing is strictly prohibited.

Healthcare distributors and medical organizations should maintain appropriate cold chain conditions during transportation and storage. Professional supply management helps ensure that products reach customers in suitable conditions.

Frequently Asked Questions

Q: What is this rabies vaccine used for after dog exposure?

A: This vaccine is designed for post-exposure rabies prevention after potential contact with rabies virus through dog bites, scratches, or other exposure situations. It helps stimulate the immune system to produce protective antibodies and is used as part of professional rabies prevention procedures.

Q: Who should consider receiving this vaccine?

A: People who experience possible rabies exposure caused by dogs may require vaccination according to medical evaluation. The appropriate vaccination plan depends on the exposure type, wound condition, and professional healthcare recommendations.

Q: What injection schedule does the product support?

A: According to the provided product information, the vaccine supports a five-dose post-exposure schedule. The recommended injection days are day 0, day 3, day 7, day 14, and day 28 after exposure. The serum-free version also supports a WHO simplified four-dose schedule according to relevant product information.

Q: What is the difference between the two available versions?

A: The conventional version uses rabies fixed virus aG strain produced through Vero cell culture technology. The serum-free version uses PV-2061 strain and applies serum-free Vero cell culture technology throughout production without bovine serum addition during the culture process.

Q: How should the vaccine be stored?

A: The Human Rabies Vaccine For Dog Bite Exposure Prevention should be stored at 2-8℃ away from light, and freezing is strictly prohibited. Maintaining proper storage and transportation conditions is important for preserving vaccine quality during distribution.

Q: Can distributors and medical organizations purchase this product in bulk?

A: AIM Honor provides professional supply cooperation for healthcare organizations, pharmaceutical distributors, and related partners. Customers can communicate with the company regarding procurement requirements, product specifications, and supply arrangements.

Q: Why choose AIM Honor as a vaccine supplier?

A: AIM Honor (Ningbo) Biopharmaceutical Co., Ltd. focuses on vaccine research, development, manufacturing, and supply. The company provides professional biological products supported by controlled production processes, technical capabilities, and long-term cooperation support for healthcare partners.

Product Summary

Developed by AIM Honor, this rabies prevention vaccine solution combines Vero cell culture technology, freeze-dried formulation, and professional manufacturing management to support medical institutions and healthcare organizations requiring reliable post-exposure vaccination products.

The product features complete specifications, professional production processes, and clear storage requirements. With established manufacturing capabilities and supply support from AIM Honor (Ningbo) Biopharmaceutical Co., Ltd., it provides a practical choice for global partners involved in rabies prevention and healthcare services.

For hospitals, distributors, and healthcare procurement organizations seeking a dependable vaccine supplier, AIM Honor provides professional product information, cooperation support, and supply solutions to meet different market needs.